 |
|
Metyrapone as Additive Treatment in Major Depression
A Double-blind and Placebo-Controlled Trial
Holger Jahn, MD;
Mildred Schick, MD;
Falk Kiefer, MD;
Michael Kellner, MD;
Alexander Yassouridis, PhD;
Klaus Wiedemann, MD
Arch Gen Psychiatry. 2004;61:1235-1244.
Background Inhibitors of steroid synthesis have been reported to exert antidepressive effects, according to preliminary findings.
Objective To test whether the addition of metyrapone to standard antidepressants induces a more rapid, more efficacious, and sustained treatment response in patients with major depression.
Design Double-blind, randomized, placebo-controlled trial.
Setting Hospitalized care.
Patients Sixty-three inpatients with a DSM-IV diagnosis of major depression and a baseline score 18 points or higher on the Hamilton Rating Scale for Depression.
Interventions Random allocation to 2 treatment groups receiving either placebo or metyrapone (1 g/d) for the first 3 weeks during a 5-week treatment with standard serotonergic antidepressants (nefazodone or fluvoxamine).
Main Outcome Measures Primary outcome criteria were the number of responders and the time to onset of action. Responder rates were considered twice after 3 and 5 weeks with a definition of treatment response as 30% and 50% reduction, respectively, of baseline Hamilton Rating Scale for Depression scores. Onset of action was defined as the time point at which at least a 20% reduction of baseline Hamilton Rating Scale for Depression scores occurred.
Results Using intention-to-treat analysis, we found that a higher proportion of patients receiving metyrapone showed a positive treatment response at day 21 (23 of 33 patients) and at day 35 (19 of 33 patients) compared with placebo patients (day 21: 13 of 30 patients; Fisher exact P = .031; day 35: 10 of 30 patients; Fisher exact P = .047). The clinical course of patients treated with metyrapone showed an earlier onset of action (Kaplan-Meier analysis; log-rank test P<.006) beginning in the first week. The plasma concentrations of corticotropin and deoxycortisol were significantly higher during metyrapone treatment (multivariate analysis of covariance, P<.05), whereas cortisol remained largely unchanged. Metyrapone treatment was well tolerated without serious adverse effects.
Conclusions Metyrapone is an effective adjunct in the treatment of major depression, accelerating the onset of antidepressant action. A better treatment outcome compared with standard treatment and a sustained antidepressive effect were observed.
Author Affiliations: Department of Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf, Hamburg (Drs Jahn, Schick, Kiefer, Kellner, and Wiedemann), and Department of Biostatistics at the Max-Planck-Institute of Psychiatry, Munich (Dr Yassouridis), Germany.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Antiglucocorticoids in psychiatry
McIsaac et al.
Adv. Psychiatr. Treat. 2009;15:242-249.
ABSTRACT
| FULL TEXT
Targeting the HPA axis in major depression: does it work?: INVITED COMMENTARY ON... ANTIGLUCOCORTICOIDS IN PSYCHIATRY
Claes
Adv. Psychiatr. Treat. 2009;15:250-252.
ABSTRACT
| FULL TEXT
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
Anderson et al.
J Psychopharmacol 2008;22:343-396.
ABSTRACT
The glucocorticoid receptor: part of the solution or part of the problem?
Pariante
J Psychopharmacol 2006;20:79-84.
ABSTRACT
Augmentation and combination strategies for depression
DeBattista
J Psychopharmacol 2006;20:11-18.
ABSTRACT
Metyrapone is an effective adjuvant treatment for major depression
Young
Evid. Based Ment. Health 2005;8:72-72.
FULL TEXT
Other articles noted
Evid. Based Med. 2005;10:95-96.
FULL TEXT
A Therapeutic Approach to Hypercortisolism in Depression
JWatch Psychiatry 2005;2005:8-8.
FULL TEXT
|
